Predictive technique could help determine breast cancer therapies

Stephen FellerATLANTA, Oct. 5 (UPI) -- Researchers at the Georgia Institute of Technology have developed a predictive model that can provide doctors with a predictive "invasiveness index" for cancer.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

Bioconjugate ChemistryDOI: 10.1021/acs.bioconjchem.9b00028
Source: Bioconjugate Chemistry - Category: Biochemistry Authors: Source Type: research
About one third of primary care providers discussed breast cancer treatment decisions with their patients, a new survey shows -- but it's not really their job.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ConclusionsThese findings demonstrate that aesthetic treatments for side-effects of cancer therapies can alleviate perceived distress and improve skin symptoms and HRQoL.
Source: Quality of Life Research - Category: Health Management Source Type: research
(Natural News) In case you still weren’t sure about whether or not cancer is one of the worst things that can ever happen to anyone, you only need to look at what happens with most female cancer patients after they have undergone treatment. In the case of breast cancer patients, it’s possible to suffer from...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
CONCLUSIONS: In the neoadjuvant setting, there is high- to low-certainty evidence of equivalent outcomes for the sequence in which taxanes are delivered. In the adjuvant setting, none of the studies reported on overall survival or disease-free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full-text publication of a relevant neoadjuvant study for women with HER2-negative breast cancer for inclusion in an update of this review. PMID: 30776132 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
In conclusion, our findings indicate that GPR120 acts as a cancer-promoting receptor in the development of breast cancer. Therefore, GPR120 is expected to be a potential new target for cancer therapy.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
n K. Iyer Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations, we report a new conjugate between the clinically approved PDL1 antibody (PDL1 AB) and drug Doxorubicin (Dox), named PDL1-Dox. We conjugated PDL1-Dox through a hydrazone linker containing a polyethylene glycol (PEG) spacer, which allows it to dissociate in a tumor environment and improves solubility. The purpose of using Dox is t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 13 February 2019Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Sharad S. Singhal, Ravi Salgia, Sulabh Singhal, David Horne, Sanjay AwasthiAbstractBreast cancer (BC) is the most common cancer among women worldwide. Due to its complexity in nature, effective BC treatment can encounter many challenges. The human RALBP1 gene encodes a 76-kDa splice variant protein, RLIP (ral-binding protein1, RalBP1), a stress-protective mercapturic acid pathway (MAP) transporter protein, that also plays a key role in regulating clathrin-dependent endocytosis (CDE) as a Ral effector...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
hamed El-Tanani The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (N...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Health